RAFI is a recombinant antimicrobial therapy targeting Vibrio anguillarum infections in aquaculture. This pathogen is a major cause of mortality in fish stocks, particularly in larvae, leading to significant economic losses worldwide. Previous approaches—including antibiotics and vaccines—have proven insufficient: antibiotics have promoted resistance, and vaccines are ineffective in early-stage fish. RAFI addresses these limitations by combining bacteriophages with antimicrobial peptides in a single recombinant system. This dual strategy harnesses phage specificity and peptide potency, offering adaptive and targeted elimination of fish pathogens. The efficacy and potential synergy of this approach will be assessed through controlled in vitro experiments.